Introduction：Basic information about CAS 752222-83-6|GS 6201, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | GS 6201 |
|---|
| CAS Number | 752222-83-6 | Molecular Weight | 446.42600 |
|---|
| Density | 1.44 | Boiling Point | 538.4ºC at 760 mmHg |
|---|
| Molecular Formula | C21H21F3N6O2 | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | 3-ethyl-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-8H-purine-2,6-dione |
|---|
| Synonym | More Synonyms |
|---|
GS 6201 BiologicalActivity
| Description | GS-6201 (CVT-6883) is a selective adenosine A2B receptor antagonist. GS-6201 displays high affinity and selectivity for the human adenosine A2B receptors (Ki=22 nM)[1]. GS-6201 reduces caspase-1 activity in the heart, and attenuates cardiac remodeling after acute myocardial infarction (AMI) in the mouse[2]. GS-62013 attenuates the airway reactivity induced by NECA, AMP, or allergen in sensitized mice[3]. |
|---|
| Related Catalog | Research Areas >>Inflammation/ImmunologySignaling Pathways >>GPCR/G Protein >>Adenosine Receptor |
|---|
| Target | Ki: 22 nM (human A2B receptors), 1070 nM (human A3 receptors), 1940 nM (human A1 receptors), 3280 nM (human A2A receptors)[1] |
|---|
| In Vivo | GS-6201 (CVT-6883) (4 mg/kg; i.p.; every 12 h for 14 days) significantly reduces IL-6, TNF-α, E-selectin, ICAM-1, and VCAM plasma levels[2]. GS-6201 (4 mg/kg; i.p.; every 12 h for 14 days) leads to a significant attenuation of left and right ventricular enlargement and dysfunction at 7 days, which was maintained at 14 days and also at 28 days[2]. GS-6201 (2 mg/kg; p.o.) treatment shows the Cmax, dAUC and t1/2 are 1110 ng/mL, 6500 ng h/mL, and 4.25 hours, respectively[1]. Animal Model: Adult out-bred male CD1 mice (8-12 weeks of age, AMI model)[2] Dosage: 4 mg/kg Administration: i.p.; every 12 h for 14 days Result: Significantly reduced IL-6, TNF-α, E-selectin, ICAM-1, and VCAM plasma levels. Animal Model: Sprague-Dawley rats[1] Dosage: 2 mg/kg Administration: p.o. (Pharmacokinetic Analysis) Result: The Cmax, dAUC and t1/2 were 1110 ng/mL, 6500 ng h/mL, and 4.25 hours, respectively. |
|---|
| References | [1]. Elzein E, et al. Discovery of a novel A2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases. J Med Chem. 2008 Apr 10;51(7):2267-78. [2]. Toldo S, et al. GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J Pharmacol Exp Ther. 2012 Dec;343(3):587-95. [3]. Mustafa SJ, et al. Effect of a specific and selective A(2B) adenosine receptor antagonist on adenosine agonist AMP and allergen-induced airway responsiveness and cellular influx in a mouse model of asthma. J Pharmacol Exp Ther. 2007 Mar;320(3):1246-51. |
|---|
Chemical & Physical Properties
| Density | 1.44 |
|---|
| Boiling Point | 538.4ºC at 760 mmHg |
|---|
| Molecular Formula | C21H21F3N6O2 |
|---|
| Molecular Weight | 446.42600 |
|---|
| Exact Mass | 446.16800 |
|---|
| PSA | 90.50000 |
|---|
| LogP | 3.24680 |
|---|
| Index of Refraction | 1.64 |
|---|
| InChIKey | KOYXXLLNCXWUNF-UHFFFAOYSA-N |
|---|
| SMILES | CCCn1c(=O)c2[nH]c(-c3cnn(Cc4cccc(C(F)(F)F)c4)c3)nc2n(CC)c1=O |
|---|
| Storage condition | -20°C |
|---|
Synonyms
| 1H-Purine-2,6-dione,3-ethyl-3,7-dihydro-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]-1H-pyrazol-4-yl]-(9CI) |
| 1H-Purine-2,6-dione,3-ethyl-3,9-dihydro-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]-1H-pyrazol-4-yl] |
| 3-ETHYL-1-PROPYL-8-(1-(3-(TRIFLUOROMETHYL)BENZYL)-1H-PYRAZOL-4-YL)-1H-PURINE-2,6(3H,8H)-DIONE |
| 3-ethyl-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione |
| CVT 6883 |
| 8-(1-(3-(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-3-ethyl-1-propyl-1H-purine-2,6(3H,7H)-dione |
